vascul
defin
inflammatori
process
blood
vessel
secondari
condit
constitut
primari
case
idiopath
disord
underli
condit
secondari
vasculitid
infecti
diseas
connect
tissu
diseas
hypersensit
disord
immun
complex
supposedli
compos
microbi
antigen
case
underli
infecti
diseas
autoantigen
connect
tissu
diseas
nonmicrobi
exogen
antigen
hypersensit
disord
involv
mani
case
pathophysiolog
secondari
vasculitid
tabl
besid
infecti
agent
may
directli
invad
blood
vessel
wall
lead
vascul
primari
vasculitid
classifi
accord
size
vessel
involv
histopatholog
lesion
certain
clinic
autoimmun
review
content
list
avail
sciencedirect
autoimmun
review
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
ev
e
r
c
l
c
e
u
rev
symptom
tabl
mention
consid
idiopath
condit
case
howev
increas
evid
microbi
agentsinfect
play
role
pathogenesi
primari
vasculitid
well
review
role
infecti
agent
primari
vasculitid
discuss
special
attent
given
wegen
granulomatosi
initi
studi
suggest
parvoviru
herp
virus
includ
herp
simplex
viru
varizellazosterviru
human
herp
viru
involv
pathogenesi
giant
cell
arter
presenc
virus
lesion
tissu
patient
diseas
suggest
base
posit
pcr
result
recent
studi
larger
number
patient
inclus
adequ
control
tissu
could
howev
confirm
find
furthermor
base
season
geograph
variat
present
infecti
agent
suggest
giant
cell
arter
proof
involv
lack
takayasu
arter
infecti
agent
demonstr
involv
diseas
pathogenesi
howev
cellular
immun
respons
mycobacteri
protein
particular
heat
shock
protein
observ
patient
takayasu
arter
relev
find
pathogenesi
diseas
highli
question
respons
present
healthi
control
well
one
howev
awar
aortiti
may
result
infect
particularli
syphili
respect
mediums
vasculitid
polyarter
nodosa
pan
associ
hepat
b
viru
hbv
infect
note
long
time
depend
geograph
area
particular
preval
hbv
infect
area
differ
percentag
given
around
patient
pan
carrier
hbv
test
hbv
patient
pan
import
hbv
infect
determin
clinic
present
treatment
outcom
patient
hbvpan
glomerulonephr
ancaposit
relaps
diseas
almost
never
found
treatment
consist
corticosteroid
togeth
antivir
agent
plasma
exchang
treatment
aim
attain
seroconvers
stop
viral
replic
gener
result
complet
remiss
diseas
without
occurr
relaps
prevent
longterm
hepat
complic
panlik
syndrom
also
report
patient
human
immunodefici
viru
hiv
infect
differ
vasculit
syndrom
encount
patient
includ
pan
kawasakilik
syndrom
primari
angiiti
central
nervou
system
small
vessel
vascul
mani
case
symptom
specif
may
suggest
manifest
hivdiseas
result
delay
diagnosi
treatment
associ
vascul
kawasaki
diseas
intrigu
inflammatori
vascul
earli
childhood
coronari
arteri
frequent
affect
suggest
diseas
result
abnorm
immunolog
respons
possibl
variou
microbi
agent
genet
suscept
infant
virus
suggest
involv
new
corona
viru
hiv
adenoviru
etc
also
superantigen
deriv
staphylococcu
aureu
implic
superantigen
protein
bind
mhc
class
ii
molecul
antigen
present
cell
interact
simultan
specif
segment
tcell
receptor
tcr
abl
stimul
antigenindepend
way
tcell
util
particular
group
tcr
segment
kawasaki
diseas
aureu
strain
isol
express
variou
superantigen
particular
toxicshocksyndrom
superantigen
analysi
repertoir
tcr
circul
tcell
show
tcell
expans
compat
superantigen
driven
tcell
prolifer
howev
exact
role
aureu
kawasaki
diseas
far
clarifi
small
vessel
vasculitid
infecti
agent
suggest
involv
diseas
pathogenesi
variou
disord
hepat
c
viru
hcv
infect
global
preval
around
associ
mix
cryoglobulinemia
around
infect
patient
cryoglobulinem
vascul
patient
strike
differ
percentag
patient
northern
europ
southern
europ
particular
itali
wherea
minor
patient
mix
cryoglobulinem
vascul
northern
europ
posit
hcv
major
patient
disord
itali
test
posit
reason
differ
known
clinic
spectrum
form
vascul
variabl
rang
purpura
sever
prolif
glomerulonephr
hcv
induc
bcell
activ
prolifer
result
product
monoclon
rheumatoid
factor
essenti
compon
mix
cryoglobulin
present
clear
howev
detect
hcv
patient
essenti
cryoglobulinem
vascul
utmost
import
therapeut
consequ
combin
antivir
treatment
interferon
alpha
ribavirin
immunosuppress
treatment
rituximab
alon
steroid
cyclophosphamid
even
plasma
exchang
sever
case
suggest
henoch
purpura
hsp
frequent
occur
form
system
vascul
childhood
character
deposit
iga
within
vessel
wall
etiolog
unknown
develop
relaps
describ
conjunct
infect
relat
multitud
microorgan
recent
studi
pediatr
case
hsp
infect
consid
trigger
diseas
patient
data
need
confirm
antineutrophil
cytoplasm
autoantibodi
anca
associ
vasculitid
compris
wegen
granulomatosi
wg
microscop
polyangi
mpa
renal
limit
form
churgstrauss
syndrom
wg
strongli
associ
antibodi
proteinas
mpa
antibodi
myeloperoxidas
mpo
sever
report
suggest
season
variat
present
form
vascul
may
suggest
microbi
involv
howev
specif
microorgan
detect
caus
agent
diseas
wg
howev
special
attent
given
aureu
chronic
nasal
carriag
aureu
occur
around
patient
wg
contrast
around
healthi
control
furthermor
chronic
nasal
carriag
concur
strongli
increas
risk
rel
risk
diseas
relaps
fig
mechan
underli
increas
risk
relaps
clarifi
sever
hypothes
formul
first
superantigen
aureu
may
stimul
bandor
tcell
inde
second
studi
wg
patient
chronic
intermitt
carrier
aureu
carri
least
one
strain
posit
superantigen
presenc
toxicshocksyndrom
superantigen
particularli
associ
strong
risk
relaps
rel
risk
furthermor
tcell
activ
observ
patient
wg
even
quiescent
phase
diseas
howev
repertoir
expand
tcell
associ
carriag
specif
aureu
superantigen
mechan
superantigen
stimul
may
oper
well
aureu
may
activ
bcell
polyclon
cellwal
compon
bacterium
polyclon
stimul
may
result
persist
anca
inde
persist
anca
induct
remiss
wg
strong
risk
factor
relaps
relat
chronic
nasal
carriag
aureu
aureu
may
also
directli
prime
neutrophil
lead
amongst
surfac
express
proteinas
target
antigen
anca
wg
prime
neutrophil
express
fulli
activ
result
damag
tissu
especi
vessel
wall
shown
cation
enzym
aureu
particular
aureu
deriv
acid
phosphatas
bind
endotheli
cell
local
also
glomeruli
antibodi
phosphatas
present
patient
wg
may
thu
bind
aureu
deriv
acid
phosphatas
deposit
kidney
inde
phosphatas
detect
renal
biopsi
patient
wg
furthermor
renal
perfus
phosphatas
rat
immun
enzym
result
sever
necrot
crescent
glomerulonephr
histopatholog
equival
renal
lesion
wg
final
new
mechan
base
presenc
complementari
protein
possibl
relat
aureu
recent
describ
studi
antibodi
describ
patient
wg
direct
complementari
protein
translat
antisens
dna
strand
encod
addit
author
show
immun
mice
complementari
induc
antibodi
protein
also
fig
diseasefre
interv
patient
wegen
granulomatosi
group
accord
staphylococcu
aureu
carrier
statu
time
diseasefre
interv
count
begin
recent
period
diseas
activ
either
initi
diagnosi
relaps
pb
ref
permiss
tabl
mechan
aureu
may
induc
exacerb
wegen
granulomatosi
interestingli
peptid
complementari
show
strong
homolog
peptid
aureu
peptid
aureu
could
molecular
mimicri
induc
antibodi
complementari
turn
via
idiotypicantiidiotyp
interact
could
induc
antibodi
characterist
autoantibodi
wg
data
confirm
extend
conclus
carriag
aureu
seen
patient
wg
associ
persist
posit
relaps
diseas
variou
mechanist
explan
relationship
support
experiment
clinic
data
tabl
exact
way
aureu
modul
diseas
express
wg
need
studi
involv
aureu
wg
may
also
therapeut
consequ
doubleblind
placebocontrol
studi
patient
receiv
mainten
treatment
cotrimoxazol
mg
bid
order
test
hypothesi
approach
could
reduc
occurr
relaps
patient
wg
treatment
led
strong
decreas
incid
mostli
respiratori
infect
howev
importantli
incid
relaps
decreas
rel
risk
second
studi
patient
activ
limit
wg
diseas
limit
upper
airway
receiv
treatment
cotrimoxazol
mg
bid
without
corticosteroid
immunosuppress
patient
reach
complet
remiss
patient
partial
remiss
median
period
month
howev
patient
relaps
median
time
month
particularli
patient
carri
aureu
diseas
extend
outsid
ent
region
unpublish
observ
data
also
support
role
microbi
agent
wg
infecti
agent
probabl
involv
diseas
induct
diseas
express
mani
case
primari
system
vascul
hepat
c
viru
infect
associ
case
cryoglobulinem
vascul
southern
europ
less
frequent
northern
europ
hepat
b
viru
infect
associ
polyarter
nodosa
decreas
incid
chronic
carriag
staphylococcu
aureu
strong
risk
factor
relaps
wegen
granulomatosi
staphylococcu
aureu
may
exacerb
wegen
granulomatosi
via
differ
mechan
monotherapi
cotrimoxazol
effect
patient
activ
wegen
granulomatosi
limit
upper
airway
particularli
chronic
carrier
staphylococcu
aureu
